Gonadorelin vs Kisspeptin-10
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Gonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profileKisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profile| Gonadorelin | Kisspeptin-10 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse | KP-10, Metastin(112-121), KISS1R agonist |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 50mcg–200mcg mcg, 2–3x per week subcutaneous | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) |
| Administration | Subcutaneous injection, Intranasal (pulsatile delivery) | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) |
| Key side effects | Injection site reactions, Headache, Nausea, Flushing | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: Gonadorelin is research-stage, while Kisspeptin-10 is fda-approved.
- Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses).
- Frequency: Gonadorelin is typically 2–3x per week subcutaneous; Kisspeptin-10 is 1–2x daily (pulsatile administration is important — avoid continuous infusion).
- Research depth: this profile cites 2 sources for Gonadorelin vs 3 for Kisspeptin-10.
How each works
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.